Vaccine Hesitancy refers to the reluctance or refusal to vaccinate despite the availability of vaccines, posing a significant challenge to public health efforts to control and prevent vaccine-preventable diseases. Vaccine hesitancy can stem from various factors, including concerns about vaccine safety, efficacy, and necessity, as well as misinformation, complacency, and lack of trust in healthcare systems or authorities. One of the primary drivers of vaccine hesitancy is misinformation and myths surrounding vaccines, fueled by social media, conspiracy theories, and anti-vaccine movements. These sources often spread false or misleading information about vaccine ingredients, side effects, and alleged risks, leading to confusion and distrust among the public.
Fear of adverse reactions or side effects is another common reason for vaccine hesitancy. While serious adverse events following vaccination are rare, they can occur, leading some individuals to perceive vaccines as unsafe or unnecessary. Addressing these concerns requires transparent communication about vaccine safety data, risk-benefit assessments, and the importance of vaccination in preventing serious diseases. Complacency, or the perception that vaccine-preventable diseases are no longer a threat, can also contribute to vaccine hesitancy. In communities where disease incidence is low or eradicated, individuals may underestimate the importance of vaccination and delay or forgo immunization, leading to outbreaks and resurgence of preventable diseases. Lack of trust in healthcare providers, pharmaceutical companies, or government authorities can further exacerbate vaccine hesitancy. Historical injustices, systemic inequalities, and incidents of medical malpractice or corruption may erode trust in vaccination programs and undermine confidence in vaccine recommendations.
Title : A universal AI design framework and brokerage platform for democratised manufacturing of mRNA therapeutics
Duccio Medini, BioForge, United States
Title : Personalized and Precision Medicine (PPM) via biodesign-driven translational applications and upgraded business modeling to secure the human biosafety: The next-step vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Development of VSV-vector based vaccine against H5N1 avian influenza by targeting both H5N1 hemagglutinin and matrix protein 2
Zhujun Ao, University of Manitoba, Canada
Title : A novel responsive microneedle platform for reliable drug and vaccine delivery
Huanhuan Li, Queen’s University Belfast, United Kingdom
Title : Emerging nanovaccine strategies for enhanced immune targeting and vaccine performance
Aysel Sadayli, V.Y. Axundov Scientific-Research Institute of Medical Prophylaxis, Azerbaijan
Title : The promise of nanotechnology in Personalized & Precision Medicine: Nano-driven precision vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Reaching zero-dose children through adaptive immunization strategies in security-compromised areas of Zamfara State, Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Comparative efficacy of different H9N2 avian influenza virus inactivated vaccines using some commercially available adjuvants for superior control in broilers
Ayman H M El Deeb, Cairo University, Egypt
Title : Structure-based design and development of next-generation Respiratory Syncytial Virus (RSV) vaccine
Lei Chen, Yikang Biotech Suzhou Co., Ltd, China
Title : Unmasking urban immunization inequities: A cross-sectional LQAS analysis of zero-dose drivers in slum and non-slum settings of Uttar Pradesh, India
Ashish Kumar Maurya, John Snow India, India